Quantcast
Synthetic Biology On Ordinary Paper Results Off The Page

Synthetic Biology On Ordinary Paper, Results Off The Page

Provided by Kat J. McAlpine, Wyss Institute for Biologically Inspired Engineering By combining efforts and innovations, Wyss Institute scientists develop synthetic gene controls for programmable diagnostics and biosensors, delivered out of the...

Latest gene expression Stories

2014-10-29 08:32:40

Data Presented This Week at the 84th Annual Meeting of the American Thyroid Association SOUTH SAN FRANCISCO, Calif., Oct. 29, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced new data from two studies supporting the use of the company's Afirma Gene Expression Classifier (GEC) to help reduce unnecessary surgeries among patients whose thyroid nodules are indeterminate for cancer following...

2014-10-14 16:27:09

LONDON, Oct. 14, 2014 /PRNewswire/ -- This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report also provides forecasts for market...

2014-10-07 16:26:26

DUBLIN, Oct. 7, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "RNA Analysis/Transcriptomics Market by Technology, by Application, by End-User - Global Forecast to 2019" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown...

2014-10-07 12:31:14

Agreement strengthens New England Biolabs' position as a key supplier to the RNA synthesis sector IPSWICH, Mass., Oct. 7, 2014 /PRNewswire/ -- New England Biolabs, Inc. (NEB(®)) has strengthened its position as a key supplier to the fast-growing RNA synthesis market by signing an agreement to supply critical reagents to TriLink BioTechnologies, Inc., a leading manufacturer of mRNA and long RNA for research, diagnostic and therapeutic applications. ?Under the terms of the agreement,...

2014-09-29 08:29:58

MARLBOROUGH, Mass., Sept. 29, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 13(th) Annual BIO Investor Forum on Tuesday, October 7, 2014 at 10:00 a.m. PST. Dr. Cauwenbergh will...

2014-09-26 16:23:31

DALLAS, September 26, 2014 /PRNewswire/ -- According to the new market research report "RNA Analysis/Transcriptomics Market by Technology (Microarray, PCR, NGS, RNAi), by Application (Clinical Diagnostics, Drug Discovery, Toxicogenomics), by End-User (Academic Research, Pharmaceutical and Biotech Companies) - Global Forecast to 2019", published by MarketsandMarkets, the global Transcriptomics Market is estimated to be worth $1985.5 Million by the end of 2014 and is expected to...

2014-09-19 16:24:35

DUBLIN, September 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/j8jfz4/global) has announced the addition of the "Global Transcriptomics Market 2014-2018" [http://www.researchandmarkets.com/research/j8jfz4/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Transcriptomics studies involve the collection and analysis of transcriptomes of different types of cells or tissues of...

2014-09-18 08:29:06

MARLBOROUGH, Mass., Sept. 18, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7(th) Annual BioPharm America(TM) Conference on Wednesday, September 24, 2014 at 11:20 a.m. EDT. Dr....

2014-09-18 08:24:06

ST. LOUIS, Sept. 18, 2014 /PRNewswire/ -- U.S. biotech company Kultevat has strengthened its technology portfolio by signing an exclusive license for technology developed by the Donald Danforth Plant Science Center to control gene expression in plants, including for applications in production of natural rubber in Taraxicum species. http://photos.prnewswire.com/prnvar/20140917/146847 The technology was developed under the direction of Roger Beachy, Ph.D., chief science officer at...

2014-09-17 08:29:00

Patents granted by the United States Patent and Trademark Office and European Patent Office and a notice of allowance from the Japanese Patent Office broaden the breadth of the Company's delivery technology platform MARLBOROUGH, Mass., Sept. 17, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.